A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

January 27, 2025

Primary Completion Date

July 31, 2029

Study Completion Date

July 31, 2029

Conditions
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Interventions
DRUG

Obinutuzumab

Intravenous Infusion

DRUG

ABBV-453

Oral; Tablet

Trial Locations (21)

2050

Royal Prince Alfred Hospital /ID# 263129, Sydney

3084

Austin Health /ID# 256776, Heidelberg

4215

Gold coast University Hospital /ID# 255785, Southport

6000

Royal Perth Hospital /ID# 256464, Perth

12203

Charite Universitaetsmedizin Berlin - Campus Benjamin Franklin /ID# 263433, Berlin

20132

IRCCS Ospedale San Raffaele /ID# 263064, Milan

20246

Universitaetsklinikum Hamburg-Eppendorf /ID# 263730, Hamburg

24105

Universitaetsklinikum Schleswig-Holstein - Campus Kiel /ID# 263150, Kiel

40138

IRCCS AOU di Bologna Policlinico Sant Orsola Malpighi /ID# 263065, Bologna

59102

Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana /ID# 264622, Billings

70300

Yitzhak Shamir Medical Center /ID# 257626, Ẕerifin

77030

MD Anderson Cancer Center /ID# 253713, Houston

89081

Universitaetsklinikum Ulm /ID# 263148, Ulm

91010

City of Hope /ID# 253904, Duarte

91120

Hadassah Medical Center-Hebrew University /ID# 254721, Jerusalem

92618

City of Hope Orange County Lennar Foundation Cancer Center /ID# 267158, Irvine

5265601

The Chaim Sheba Medical Center /ID# 254383, Ramat Gan

28204-2963

Atrium Health /ID# 265136, Charlotte

27710-3000

Duke Cancer Center /ID# 258707, Durham

06120

Universitaetsklinikum Halle (Saale) /ID# 263299, Halle

06156

Azienda Ospedaliera di Perugia - Ospedale S. Maria della Misericordia /ID# 263062, Perugia

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AbbVie

INDUSTRY